{"id":920493,"date":"2025-12-17T07:09:43","date_gmt":"2025-12-17T12:09:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"modified":"2025-12-17T07:09:43","modified_gmt":"2025-12-17T12:09:43","slug":"entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, Dec.  17, 2025  (GLOBE NEWSWIRE) &#8212; Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET).<\/p>\n<p>A live webcast will be available on the Presentations portion of Entrada\u2019s Investor Relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZnbD62M3qZwesO_fz8j41ucC1G_uQGn5CGLYFSYtZ30_MlrkvcTSMBWF2itc_Wl3rEB0H9DJdFDiNjFg8l9TafsqsbyFJCRWsUU3xrOMa779wNXTDFeMhf3ePWPKP6_KYNJ6mceEso0lYIc_PSKOI_xbkGqbuDqoBRwUIXdhY_JcH9yt7LiGPZ1ryvpZ8KsY8i7VE_s2vE45hhzMl4Oxdcyw71sXGap3KEn7xOEdaaIdpx9ajxPJ252JsInMGZIK06dV-GBu2cD_mU2YmCfnNw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.entradatx.com<\/a>. The webcast will be archived and available for replay for 30 days after the event.<\/p>\n<p>\n        <strong>About Entrada Therapeutics<\/strong><br \/>\n        <br \/>Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company\u2019s Endosomal Escape Vehicle (EEV\u2122)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The Company\u2019s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.<\/p>\n<p>For more information about Entrada, please visit our website,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C3afaw1bd6Qe4TTZB01_pY8XcNz-lQ1S3Ec9auF9w92vu6KPioitH9mNyZBxdVo5Fbq30tWaJhHoq_aKKnB_2pPemzWbCppdghjk5WVR9872SjINgfrAsY8SNxrfXsZI8lEEymOOrn_VKODhWTYWrreybzaHMCLNpVp0fReoOKsCg5mAQKZkbKyGfUuZTLMCfBlZXC_OTO6oJF6mGXJnOOkbTuYdIduOd7Bae2SNqvX9WFsFLeItyjHU7PQ1QdAlDMxjhrKi3ifEPcBC8i7L5Q==\" rel=\"nofollow\" target=\"_blank\"><u>www.entradatx.com<\/u><\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WUU8LBzE4TE02mzhauiQ0xejfzHESmN-GunEReUjDTpUyH5ZeFNPPLrnulkPd07d6mRcGnehJK23Q-AXxVgGAgi2rdMAL1RvQE06TzENoyVpnVHOpCV4wPoYT2o7QsycB8twlvZWuzgmk5VJbaHOIWQXWEwW0Hw7QilvqNRO-Hu7NWrH-IzewN55Uff3MA-5fbKyEOhpWfW8BRI5MPDTqKSG_dqd-7xIpUq1JrSzJGF6Qpax0S8OWt8TiNst3CTZ\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Karla MacDonald<br \/>Chief Corporate Affairs Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ygFsIETu--6sl9aqYH2MJiYNxx3OKwkKchuLF1EFKQC0i_8rNir9EMrUz4Kqf38WDuASImOJLlsf77U88bTgoYoEr8ALqbxwJxdyD6q_tATaXI9TSZWC8kV90WulRHVL\" rel=\"nofollow\" target=\"_blank\">kmacdonald@entradatx.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Megan Prock McGrath<br \/>CTD Comms, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0GuUDbsOV9mbuASpNxI7tfP4WrWWrUgLFdbYEqkA07Oui9e5MMeC9v6otycAahQ83K-hLeSjwshPuCZLDtNy9nApfqw68XgbU7W3WchtUDc=\" rel=\"nofollow\" target=\"_blank\">megan@ctdcomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWJmYjk0OTYtOTk0Ny00NzgyLTg3MDItZGE4MzczZmY1ODM3LTEyMTIwODUtMjAyNS0xMi0xNy1lbg==\/tiny\/Entrada-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) &#8212; Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada\u2019s Investor Relations website at https:\/\/ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company\u2019s Endosomal Escape Vehicle (EEV\u2122)-therapeutics are designed to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-920493","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) &#8212; Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada\u2019s Investor Relations website at https:\/\/ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company\u2019s Endosomal Escape Vehicle (EEV\u2122)-therapeutics are designed to &hellip; Continue reading &quot;Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-17T12:09:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2025-12-17T12:09:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=\",\"datePublished\":\"2025-12-17T12:09:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) &#8212; Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada\u2019s Investor Relations website at https:\/\/ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company\u2019s Endosomal Escape Vehicle (EEV\u2122)-therapeutics are designed to &hellip; Continue reading \"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-17T12:09:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference","datePublished":"2025-12-17T12:09:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","name":"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=","datePublished":"2025-12-17T12:09:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjQ0MSM3MzIyNTY3IzIyMDA1MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entrada-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=920493"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920493\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=920493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=920493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=920493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}